

## Description générale

Ritonavir is recommended for use in combination with other protease inhibitors as a pharmacological booster in the prevention and treatment of HIV/AIDS, and not as an antiretroviral in its own right.

|                            |                                                                                                                                                                         |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| INN                        | Ritonavir                                                                                                                                                               |
| Codes ATC                  | J05AE03                                                                                                                                                                 |
| Type de médicament         | Chemical agent                                                                                                                                                          |
| Historique des statuts LME | Ajouté pour la première fois en 2002 (TRS 914) pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |
| Wikipédia                  | <a href="#">Ritonavir</a>                                                              |
| DrugBank                   | <a href="#">Ritonavir</a>                                                              |

## Recommandations

Section Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

